Cerebral Dynamic Perfusion Study With Spectral CT in Patients Suspected of Stroke

NCT ID: NCT03948425

Last Updated: 2020-11-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-08

Study Completion Date

2019-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Generate a dynamic mapping of the distribution of iodine within the cerebral parenchyma in the patient suspected of acute ischemic disorder with the CT spectral scanner.
* Correlate the anomalies of iodine mapping to the other parameters acquired during the classic dynamic infusion phase to define the ischemic area (MTT higher and rCBV normal) versus infarcted zone (MTT higher and rCBV decreased)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stroke

Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms):Intervention 'spectral CT'

Group Type EXPERIMENTAL

spectral CT

Intervention Type RADIATION

Head spectral CT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

spectral CT

Head spectral CT

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical suspicion of hyperacute stroke (6 hours after onset of symptoms)
* Age between 50 and 95 years
* Weight: between 65 and 95 kg

Exclusion Criteria

* Documented or suspected allergy to IV iodinated contrast media
* Renal impairment with creatinine clearance \<60 ml / min
* Hemorrhagic lesions or vascular abnormalities demonstrated on CT before contrast injection
Minimum Eligible Age

50 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emmanuel Coche, MD-PhD

Role: PRINCIPAL_INVESTIGATOR

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cliniques universitaires saint Luc

Brussels, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

References

Explore related publications, articles, or registry entries linked to this study.

Duprez T, Vlassenbroek A, Peeters A, Poncelet PA, Levecque E, Austein F, Pahn G, Nae Y, Abdallah S, Coche E. Preliminary experience of CT imaging of the ischaemic brain penumbra through spectral processing of multiphasic CTA datasets. Sci Rep. 2023 Jul 15;13(1):11431. doi: 10.1038/s41598-023-38370-9.

Reference Type DERIVED
PMID: 37454162 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017/12AVR/209

Identifier Type: OTHER

Identifier Source: secondary_id

AVC AIGUS

Identifier Type: -

Identifier Source: org_study_id